Taysha, UTSW start fund to speed up CNS gene therapies

By The Science Advisory Board staff writers

January 13, 2021 -- Taysha Gene Therapies and the University of Texas Southwestern Medical Center (UTSW) have launched a fund to accelerate the development of adeno-associated virus (AAV) gene therapies for monogenic diseases of the central nervous system (CNS).

Expanding this partnership supports the medical center's discovery efforts to bring about promising therapies while Taysha gets an exclusive option on new programs and intellectual property linked to this deal.


Copyright © 2021 scienceboard.net
 


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.